Direct Answer
Zoetis (ZTS) is the world's largest animal health company, selling medicines, vaccines, and diagnostics for companion animals and livestock. Spun off from Pfizer in 2013, Zoetis benefits from pet humanization (Apoquel and Cytopoint allergy blockbusters, Simparica flea/tick prevention) and global protein demand for livestock. Companion animals are now the majority of revenue and the higher-growth, higher-margin segment. The livestock business is more mature and commoditized.
Zoetis (ZTS) Business & Investor Dossier
Company Snapshot
| Ticker | ZTS (NYSE) |
|---|---|
| Founded | 1952 (as Pfizer animal health); spun off from Pfizer 2013 |
| Headquarters | Parsippany, New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Business | World's largest animal health company; Companion Animals segment (dogs, cats, horses: Apoquel, Cytopoint dermatology; Simparica Trio parasiticides; vaccines; diagnostics) and Livestock segment (cattle, swine, poultry, fish: vaccines, antibiotics, biologics, feed additives); global sales in 100+ countries |
| Notable | Pfizer spinoff (2013); pet humanization secular tailwind; Apoquel/Cytopoint blockbuster dermatology franchise; Simparica Trio combination parasiticide; companion animals now majority of revenue; post-pandemic pet spending normalization; livestock antibiotic restriction trends |
| Key Competitors | Elanco Animal Health (ELAN), Merck Animal Health (MRK subsidiary), Boehringer Ingelheim (private), IDEXX Laboratories (IDXX) in diagnostics |
What Does Zoetis Do?
Zoetis is the world's largest animal health company, developing and selling medicines, vaccines, and diagnostics for companion animals (Apoquel/Cytopoint allergy treatments, Simparica Trio parasiticides) and livestock (vaccines, biologics for cattle and swine). Spun off from Pfizer in 2013, Zoetis benefits from pet humanization trends that have made companion animals the majority of revenue and the higher-growth, higher-margin segment. The livestock business serves global protein demand but is more mature and commoditized.
Frequently Asked Questions
What does Zoetis do and how does it make money?
Zoetis is the world's largest animal health company, selling medicines, vaccines, diagnostics, and technologies for animals. Companion Animals (pets, horses): medicines for parasites (Simparica Trio, Revolution), dermatology/allergies (Apoquel, Cytopoint), pain management, and vaccines. Now the majority of revenue. Livestock (cattle, swine, poultry, fish): vaccines, antibiotics, antiparasitics, reproductive biologics, and diagnostics. Products sold through veterinarians, distributors, and retail channels across 100+ countries. Revenue is diversified geographically with the US as the largest market.
What is the 'pet humanization' trend and how does it benefit Zoetis?
Pet humanization is the cultural shift of treating pets as family members, driving higher per-pet healthcare spending: preventive care, expensive chronic condition treatments, more frequent vet visits, and pet insurance. For Zoetis, this most directly benefits its dermatology franchise: Apoquel (oral JAK inhibitor for canine atopic dermatitis) and Cytopoint (injectable biologic for canine allergies) became blockbuster products by treating conditions previously underaddressed. The pandemic-era pet adoption surge accelerated pet ownership; post-pandemic, per-pet spending has remained elevated. Rising pet ownership in emerging markets represents additional long-term growth.
What are Zoetis' key products and their competitive moats?
Key products: Apoquel (oral JAK inhibitor for canine atopic dermatitis, strong patient base), Cytopoint (biologic injectable for canine allergies), Simparica/Simparica Trio (next-generation flea/tick/heartworm combination), Vetscan point-of-care diagnostics, Draxxin antibiotic and cattle/swine vaccines. Competitive moats include scale R&D capability (largest animal health company can fund development smaller competitors cannot), regulatory approval barriers (multi-year approval timelines create moats similar to human pharma but faster), established veterinary relationships and brand trust, and portfolio breadth across species and indications.
How does Zoetis' livestock business compare to companion animals?
Companion animal is the growth engine: pet humanization and premiumization drive volume and pricing power; it represents the majority of Zoetis' revenue with much higher margins. Livestock is more mature: serving food animal producers, it is more commoditized and price-sensitive, subject to protein price cycles, and faces antibiotic use restriction trends in some markets. Livestock has been the slower-growing segment but Zoetis holds leading positions in cattle and swine biologics. The strategic narrative at Zoetis increasingly emphasizes companion animal growth while managing livestock for cash flow.
What are the main risks for Zoetis?
Key risks include pet industry cyclicality (pet adoption spiked during COVID-19 then normalized, creating tough comparisons), generic competition as patents expire on key products (animal health generics are slower to develop than human pharma but a real threat), antibiotic resistance regulations in livestock (pressure to reduce food animal antibiotics), pricing pressure from veterinary consolidation (large corporate vet groups negotiate harder), currency risk (significant international revenue), and pipeline risk (new product launches require sustained R&D investment; failures reduce expected growth).